Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.18), $0.07 worse than the analyst estimate of ($1.11). Revenue for the quarter came in at $233.5 million versus the consensus estimate of $220.81 million.

GUIDANCE:

Sarepta Therapeutics sees FY2022 revenue of $905-920 million, versus the consensus of $899.9 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.